Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968978 · ClinicalTrials.gov registry record · Phase 3
Tezepelumab Home Use Study
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT03968978: Completed Phase 3 study, sponsored by AstraZeneca.
NCT03968978 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 216 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03968978, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.
Primary Outcome
Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.
Interventions
- BIOLOGICAL Tezepelumab (APFS)
- BIOLOGICAL Tezepelumab (AI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2020-06-05 |
| Phase | Phase 3 |
What the finished NCT03968978 record still lists
NCT03968978 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Tezepelumab (APFS) is the first listed.
NCT03968978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03968978 about?
NCT03968978 is a clinical study titled "Tezepelumab Home Use Study". This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered sub...
What is the current status of trial NCT03968978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2019-05-21. Estimated completion is 2020-06-05.
What interventions are being tested in trial NCT03968978?
The interventions under investigation include: Tezepelumab (APFS) (BIOLOGICAL), Tezepelumab (AI) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03968978?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03968978's enrollment target sits among peer trials
216 1332nd of 2000 higher than 667 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI